Related Experiment Video
Updated: Sep 12, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver
Huei-Tyng Huang1, Michael Hewitt1, Wenhao Li1
1Barts Liver Centre and Barts Metabolism Network, Blizard Institute, Queen Mary University of London, London, UK.
Background:
We sought to determine the changing prevalence, incidence, and temporal trends in real-world, recorded diagnoses of metabolic dysfunction-associated steatotic liver disease (MASLD) and assess availability of fibrosis risk stratification following awareness campaigns and guideline updates over the last decade.
Methods:
This population-based cohort study identified MASLD diagnoses made between 2003 and 2022 in the UK primary-care Clinical Practice Research Datalink (CPRD) to estimate prevalence and incidence. A nested case-control analysis, utilising 1:4 age-, sex-, and general practice-matched controls, assessed clinical characteristics, availability of Fibrosis-4 (Fib-4) components, and its temporal trend pre- and post-2015.
Findings:
11.7 million individuals were active in CPRD in 2022. 365,797 comprised the study cohort of people with a MASLD diagnosis (matched to 1,460,288 controls). From 2012 to 2022, recorded MASLD prevalence rose from 0.52% [N = 51,028] to 2.42% [N = 283,762] (p < 0.001); recorded incidence doubled from 1.60 to 3.31 per 1000 person-years (p < 0.001). People with MASLD diagnosis had a higher prevalence of type 2 diabetes (21.0% [N = 76,640] vs 7.7% [N = 112,812]) and hypertension (35.3% [N = 129,156] vs 18.7% [N = 273,502]). People of South Asian ethnicity were overrepresented in MASLD cohort but had the lowest availability of Fib-4 components (14.6% [N = 4467]; adjusted odds ratio 0.67, 95% CI: 0.65-0.70, vs White). Overall, Fib-4 availability increased pre-to post-2015 (4.3% [N = 4945] to 22.8% [N = 56,634]). Among those with a calculable score, fewer South Asian individuals had indeterminate/high risk (18.6% [N = 833] vs 35.3% [N = 15,115] in White individuals, p < 0.001).
Interpretation:
Recorded MASLD prevalence has increased 5-fold in a decade, yet a diagnostic gap persists. Fibrosis risk stratification has improved, but remains low and is potentially inequitable for people of South Asian ethnicity.
Funding:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Barts Charity.
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:24Cirrhosis II: Pathophysiology
01:23Cirrhosis I: Introduction
01:21Chronic Pancreatitis II: Pathophysiology
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...